middle.news
LTR Pharma Advances Rapid-Onset Intranasal ED Therapy SPONTAN with Strong Clinical Data
9:44am on Friday 1st of May, 2026 AEST
•
Healthcare
Read Story
LTR Pharma Advances Rapid-Onset Intranasal ED Therapy SPONTAN with Strong Clinical Data
9:44am on Friday 1st of May, 2026 AEST
Key Points
SPONTAN shows fivefold faster absorption than oral PDE5 tablets
Over 1,000 prescriptions via Australian TGA Special Access Scheme
Dual US pathway: FDA 505(b)(2) and personalised medicine 503A
$24.1 million cash backing Phase II and regulatory milestones
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Ltr Pharma (ASX:LTP)
OPEN ARTICLE